April 24, 2013 – Dr. McAllister presented Cytograft's clinical progress at the American Heart Association's Emerging Science Series "Innovations in Vascular Bioengineering"
      • Webinar recording available HERE.
April 17, 2013 - Dr. L’Heureux presented a webinar for young professionals on "Developing an Industry Career in Biomedical Engineering". More information available via BMES.
April 10, 2013 – Society for Biomaterials 2013 Annual Meeting- Adam Young presented on work creating dermal fillers using Cytograft's TESA technology.
December 8, 2012 - Dr. L’Heureux was invited to Tianjin to speak at the International Symposium on Small Diameter Vascular Grafts.
April 23, 2012 – Dr. L’Heureux reports a new process with cell synthesized threads at the annual FASEB meeting.
      • Press release can be found HERE.
      • Scientific American story HERE.
      • MIT Technology Review HERE.

Cytograft maintains a focused product portfolio targeted at cell-based solutions to cardiovascular disease. The company's lead product has shown promising results in phase I/II clinical trials as reported in the Lancet.

Our follow-on products include the LifeGuard™ patch and the LifeJacket™ stent-graft. These products take advantage of Cytograft's expertise in Tissue Engineering by Self-Assembly (TESA) and biological based treatments. These follow-on technologies range from discovery stage to advanced pre-clinical research to support FIM (first in man).

The company is also developing a line of surgical devices to support percutaneous bypass and other minimally invasive surgical approaches.

link to tebv link to covered stent link to patch link to percutaneous bypass link to valve

Gant Chart - Development Stage